NCT05228470 2026-01-06A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.PfizerPhase 2 Completed39 enrolled 15 charts
NCT02158858 2025-10-08A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative MalignanciesConstellation PharmaceuticalsPhase 1/2 Completed336 enrolled